- 米国企業
- Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc.HEPA
| 2014年
6月30日 | 2015年
6月30日 | 2016年
6月30日 | 2017年
6月30日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 |
|---|
| Net loss | - | -14,347,877 | -16,998,638 | -14,891,050 | -9,449,295 | -6,718,698 | -20,353,938 | -32,722,168 | -42,200,049 |
|---|
| Stock-based compensation | 195,226 | 2 | 901,867 | 2 | 234,510 | 66,176 | 2 | 5 | 3 |
|---|
| Depreciation and amortization | 1,321 | 16,355 | 21,525 | 27,993 | 18,787 | 26,737 | 34,515 | 0 | 77,461 |
|---|
| Change in fair value of contingent consideration | - | - | - | - | 265,398 | -160,000 | 140,000 | 2 | -414,992 |
|---|
| Impairment of goodwill | - | - | - | - | - | - | - | - | 2 |
|---|
| Accounts payable and accrued expenses | - | - | 3 | -2,128,263 | -897,695 | -424,357 | 3 | -1,067,847 | 2 |
|---|
| Right of use asset | - | - | - | - | - | - | - | -252,803 | -253,104 |
|---|
| Operating lease liability | - | - | - | - | - | - | - | -258,589 | -263,378 |
|---|
| Prepaid expenses and other assets | 168,621 | 563,974 | -191,973 | -287,644 | 82,021 | 330,247 | 1 | 4 | -917,308 |
|---|
| Net cash used in operating activities | - | - | - | -19,172,110 | -15,646,027 | -7,565,059 | -16,165,202 | -31 | -35 |
|---|
| Purchase of property and equipment | 15,847 | 83,269 | 6,603 | 14,709 | - | 51,469 | 87,983 | 130,405 | 16,336 |
|---|
| Proceeds from disposal of property and equipment | - | - | - | - | 900 | - | 2,194 | - | 2,266 |
|---|
| Net cash used in investing activities | - | - | - | -14,709 | 900 | -51,469 | -85,789 | -130,405 | -14,070 |
|---|
| Proceeds from Issuance of Common Stock | - | - | - | 25 | 2 | 8 | 43 | 82 | - |
|---|
| Proceeds from Issuance of Convertible Preferred Stock | - | 13 | - | - | 10 | - | - | - | 18 |
|---|
| Redemption of Series F and Series G Convertible Redeemable Preferred Stock | - | - | - | - | - | - | - | - | 21 |
|---|
| Repayment of debt financing | - | - | - | - | - | - | - | 176,585 | - |
|---|
| Contingent consideration milestone payment | - | - | - | - | 1,000,000 | - | - | - | 2 |
|---|
| Net cash (used in) provided by financing activities | - | - | - | 25 | 13 | 19 | 43 | 82 | -5,137,500 |
|---|
| Effect of exchange rates on cash | - | - | - | - | - | - | - | - | -47,138 |
|---|
| Net (decrease) increase in cash | - | - | - | - | - | 11 | 27 | 51 | -40,159,879 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | 2,024 | 941 |
|---|
| Conversion of Stock, Amount Converted | - | - | - | - | - | - | - | 11,000 | 5,000 |
|---|
| Stock Issued | - | - | - | - | - | 500,244 | - | - | 5,008 |
|---|
| Fair value of warrants issued to placement agent | - | - | - | - | - | - | - | 2 | - |
|---|
| Adoption of new accounting standard | - | - | - | - | - | - | - | 11,672 | - |
|---|